24.06.2020 MagForce AG  DE000A0HGQF5

DGAP-Adhoc: MagForce AG enters into an Agreement with Yorkville Advisors Global LP to issue Convertible Bonds in the amount of up to EUR 15 million


 

DGAP-Ad-hoc: MagForce AG / Key word(s): Financing
MagForce AG enters into an Agreement with Yorkville Advisors Global LP to issue Convertible Bonds in the amount of up to EUR 15 million

24-Jun-2020 / 17:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


MagForce AG enters into an Agreement with Yorkville Advisors Global LP to issue Convertible Bonds in the amount of up to EUR 15 million

Berlin June 24, 2020 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today signed an agreement with U.S. investment firm Yorkville Advisors Global LP ("Yorkville") for a growth financing via convertible notes of up to EUR 15 million to be drawn in probably up to five tranches.

The first tranche of EUR 2.5 million each is expected to be drawn shortly. This financing enables MagForce to further implement its commercial strategy and support the roll-out of its NanoTherm Therapy treatment system. Under the terms of the agreement, Yorkville is obligated to purchase convertible notes in a total nominal amount of up to EUR 15 million at an issue price corresponding to 95% of the nominal amount until June 2023. MagForce may, at its own discretion, issue the next tranche of convertible notes to Yorkville under certain conditions. The unsecured convertible notes each have a term of 12 months and are convertible into MagForce shares during the term by the holder of the convertible notes. MagForce can extend the term of the notes by up to 6 months against a cash fee. The conversion price shall be determined taking into account a 5% discount on the volume-weighted 5-day average trading price of the MagForce share immediately prior to conversion but may not be lower than 80% of the volume-weighted 10-day average price of the MagForce share prior to MagForce's Management Board's resolution to issue the convertible notes. Interest is not paid during the term of the notes. To the extent permitted by the authorization of the MagForce Annual General Meeting of 9 August 2018, the convertible notes are issued without subscription rights for existing shareholders. For the full utilization of the nominal amount of EUR 15 million under exclusion of subscription rights, additional authorizations may be required by the Annual General Meeting.


Contact:
MagForce AG, Max-Planck-Straße 3, 12489 Berlin
Barbara von Frankenberg
Vice President Communications & Investor Relations
T +49-30-308380-77
E-Mail: [email protected]

 


Information and Explanation of the Issuer to this News:

Saad Gilani, Head of Healthcare Investments at Yorkville, commented: 'We have been following MagForce closely for years and see the company's sustained positive development. Since the beginning of this year in particular, I think MagForce has had very good success in the treatment of brain tumors with the NanoTherm therapy system in Europe. Their approval by the FDA for the next stage of the company's pivotal U.S. prostate cancer study shows continued progress. We are pleased to be able to support MagForce with our financing on its further path and thus contribute to the company's success'.

Christian von Volkmann, CFO of MagForce AG: 'We look forward to working with Yorkville. This flexible financing instrument is an ideal component of our corporate financing and will support us in achieving our ambitious goals in the long term'.



Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as 'expects', 'aims', 'anticipates', 'intends', 'plans', 'believes', 'seeks', 'estimates' or 'will'. Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

 


24-Jun-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: [email protected]
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange
EQS News ID: 1077891

 
End of Announcement DGAP News Service

1077891  24-Jun-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1077891&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 2,58 0,47 0,72 0,07 0,84 0,62 0,00
EBITDA1,2 -1,32 -6,55 -6,74 7,43 -5,56 19,28 0,00
EBITDA-Marge3 -51,16 -1.393,62 -936,11 10.614,29 -661,90 3.109,68 0,00
EBIT1,4 -1,88 -7,46 -7,41 6,83 -6,20 18,62 0,00
EBIT-Marge5 -72,87 -1.587,23 -1.029,17 9.757,14 -738,10 3.003,23 0,00
Jahresüberschuss1 -1,55 -7,23 -7,47 4,36 -8,73 14,75 0,00
Netto-Marge6 -60,08 -1.538,30 -1.037,50 6.228,57 -1.039,29 2.379,03 0,00
Cashflow1,7 -5,13 -6,58 -5,34 -7,11 -5,67 -5,70 0,00
Ergebnis je Aktie8 -0,06 -0,28 -0,28 0,16 -0,32 0,50 -0,18
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: AIOS

INVESTOR-INFORMATIONEN
©boersengefluester.de
MagForce
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0HGQF 3,960 Halten 116,26
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 21,29 0,00 -12,77
KBV KCV KUV EV/EBITDA
3,27 - 187,21 7,30
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
Hauptversammlung
0,00 0,00 0,00 12.08.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
29.10.2021 30.06.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,67% -3,01% -20,48% 29,41%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MagForce AG  ISIN: DE000A0HGQF5 können Sie bei DGAP abrufen

Medtech , A0HGQF , MF6 , XETR:MF6